Register for our free email digests:
Translational Drug Development Inc.
Division of Translational Genomics Research Institute
Latest From LG Life Sciences Ltd.
There are 20 biosimilar adalimumab drugs in development – including one from Amgen that has already been approved but not yet launched. Biotechs and big pharma companies alike are lining up their candidates in preparation for when AbbVie's world-leading inflammation and immunology product Humira loses patent protection.
Amgen’s biosimilar version of the anti-TNF adalimumab has become the first to receive an EU positive opinion but the company has no plans to launch the product this year.
Boehringer Ingelheim is poised to submit marketing applications in the US and Europe for its biosimilar adalimumab after it showed equivalent safety and efficacy to Humira in a pivotal study.
LG's decision to merge its biopharma affiliate LG Life Sciences with the group's main cash cow, LG Chem, signals a focus on "red biotech" and a desire to keep up with other major South Korean conglomerates such as Samsung that are building their biopharma businesses. LG plans to sharply hike sector R&D and capital investments to position the combined operation as a future growth engine.
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.